PedAM

Pediatric Disease Annotations & Medicines


	raynaud disease

Disease ID	731
Disease	raynaud disease
Definition	intermittent attacks of ischemia in the fingers, toes, ears, or nose, accompanied by pain, pallor, and prickling; phenomenon applies to secondary symptoms, disease when cause is unknown.
Synonym	cold fingers, hereditary disease raynaud disease raynaud's disease raynauds raynaud raynaud dis raynaud disease [disease/finding] raynaud s disease raynaud's disease raynaud's disease (disorder) raynauds raynauds dis raynauds disease
OMIM	OMIM:179600
DOID	DOID:10300
UMLS	C0034734
MeSH	D011928
SNOMED-CT	SNOMEDCT_US_2016_09_01:195295006
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:1) C0039446 \| telangiectasias \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:3) IFNA2 \| 3440 \| CTD_human GSTM1 \| 2944 \| CTD_human GSTT1 \| 2952 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:2) 2944 \| GSTM1 \| infer 2952 \| GSTT1 \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:71) 350 \| APOH \| DISEASES 973 \| CD79A \| DISEASES 1777 \| DNASE2 \| DISEASES 1311 \| COMP \| DISEASES 3375 \| IAPP \| DISEASES 5184 \| PEPD \| DISEASES 6945 \| MLX \| DISEASES 8431 \| NR0B2 \| DISEASES 6737 \| TRIM21 \| DISEASES 1401 \| CRP \| DISEASES 6741 \| SSB \| DISEASES 7450 \| VWF \| DISEASES 8989 \| TRPA1 \| DISEASES 64377 \| CHST8 \| DISEASES 5024 \| P2RX3 \| DISEASES 5443 \| POMC \| DISEASES 3827 \| KNG1 \| DISEASES 3439 \| IFNA1 \| DISEASES 23657 \| SLC7A11 \| DISEASES 1636 \| ACE \| DISEASES 5739 \| PTGIR \| DISEASES 6294 \| SAFB \| DISEASES 213 \| ALB \| DISEASES 5473 \| PPBP \| DISEASES 85477 \| SCIN \| DISEASES 3816 \| KLK1 \| DISEASES 2357 \| FPR1 \| DISEASES 1657 \| DMXL1 \| DISEASES 3352 \| HTR1D \| DISEASES 1909 \| EDNRA \| DISEASES 6683 \| SPAST \| DISEASES 6863 \| TAC1 \| DISEASES 2149 \| F2R \| DISEASES 79054 \| TRPM8 \| DISEASES 9159 \| PCSK7 \| DISEASES 5366 \| PMAIP1 \| DISEASES 796 \| CALCA \| DISEASES 1058 \| CENPA \| DISEASES 1908 \| EDN3 \| DISEASES 155051 \| CRYGN \| DISEASES 9402 \| GRAP2 \| DISEASES 3329 \| HSPD1 \| DISEASES 8654 \| PDE5A \| DISEASES 131601 \| TPRA1 \| DISEASES 2213 \| FCGR2B \| DISEASES 7150 \| TOP1 \| DISEASES 23038 \| WDTC1 \| DISEASES 462 \| SERPINC1 \| DISEASES 2153 \| F5 \| DISEASES 6277 \| S100A6 \| DISEASES 6278 \| S100A7 \| DISEASES 3351 \| HTR1B \| DISEASES 959 \| CD40LG \| DISEASES 5476 \| CTSA \| DISEASES 1907 \| EDN2 \| DISEASES 6709 \| SPTAN1 \| DISEASES 1041 \| CDSN \| DISEASES 1910 \| EDNRB \| DISEASES 11332 \| ACOT7 \| DISEASES 9356 \| SLC22A6 \| DISEASES 51182 \| HSPA14 \| DISEASES 1906 \| EDN1 \| DISEASES 1059 \| CENPB \| DISEASES 5256 \| PHKA2 \| DISEASES 2919 \| CXCL1 \| DISEASES 831 \| CAST \| DISEASES 594857 \| NPS \| DISEASES 51428 \| DDX41 \| DISEASES 5125 \| PCSK5 \| DISEASES 6625 \| SNRNP70 \| DISEASES 102723508 \| KANTR \| DISEASES
Locus	(Waiting for update.)

Disease ID	731
Disease	raynaud disease
Integrated Phenotype	HPO \| Name(Total Integrated Phenotypes:1) HP:0000924 \| Abnormality of the skeletal system
Text Mined Phenotype	(Waiting for update.)

Disease ID	731
Disease	raynaud disease
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:1) C0039446 \| telangiectasias \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:19)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0034734	atenolol	D001262	29122-68-7	raynaud disease	MESH:D011928	marker/mechanism	6109
C0034734	bleomycin	D001761	11056-06-7	raynaud disease	MESH:D011928	marker/mechanism	1702313
C0034734	citalopram	D015283	59729-33-8	raynaud disease	MESH:D011928	marker/mechanism	17103176
C0034734	clonidine	D003000	4205-90-7	raynaud disease	MESH:D011928	marker/mechanism	2057015
C0034734	cisplatin	D002945	15663-27-1	raynaud disease	MESH:D011928	marker/mechanism	1702313
C0034734	fluorouracil	D005472	51-21-8	raynaud disease	MESH:D011928	marker/mechanism	10023329
C0034734	fluoxetine	D005473	54910-89-3	raynaud disease	MESH:D011928	marker/mechanism	9171912
C0034734	leucovorin	D002955	1958/5/9	raynaud disease	MESH:D011928	marker/mechanism	10023329
C0034734	griseofulvin	D006118	126-07-8	raynaud disease	MESH:D011928	therapeutic	5414890
C0034734	hydroxyurea	D006918	127-07-1	raynaud disease	MESH:D011928	marker/mechanism	12620292
C0034734	indomethacin	D007213	53-86-1	raynaud disease	MESH:D011928	therapeutic	6614039
C0034734	methylphenidate	D008774	113-45-1	raynaud disease	MESH:D011928	marker/mechanism	18240233
C0034734	metoprolol	D008790	37350-58-6	raynaud disease	MESH:D011928	marker/mechanism	12090909
C0034734	prazosin	D011224	19216-56-9	raynaud disease	MESH:D011928	therapeutic	6124197
C0034734	propranolol	D011433	525-66-6	raynaud disease	MESH:D011928	marker/mechanism	520027
C0034734	epoprostenol	D011464	35121-78-9	raynaud disease	MESH:D011928	therapeutic	2875251
C0034734	timolol	D013999	26839-75-8	raynaud disease	MESH:D011928	marker/mechanism	2323696
C0034734	vinblastine	D014747	865-21-4	raynaud disease	MESH:D011928	marker/mechanism	1702313
C0034734	vincristine	D014750	-	raynaud disease	MESH:D011928	marker/mechanism	15543016

FDA approved drug and dosage information(Total Drugs:3)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D011928	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D011928	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No
MESH:D011928	daytrana	methylphenidate	10MG/9HR (1.1MG/HR)	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription	None	Yes	No

FDA labeling changes(Total Drugs:3)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D011928	6/4/2006	daytrana	methylphenidate	ADHD	Summary is pending	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D011928	12/14/2009	daytrana	methylphenidate	Postmarketing safety study	Information added to Warnings and Adverse Reactions on skin reactions observed in a postmarketing dermal study in pediatric patients	Labeling	-	P	-	-	Shire	-	FALSE'
MESH:D011928	06/29/2010	daytrana	methylphenidate	ADHD	Expanded pediatric indication to include adolescent patients ages13-17 years The most commonly reported adverse reactions in a trial in patients 13-17 years included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia. The majority of patients had erythema at the application site Information on PK parameters, Adverse Event profile and clinical studies	Labeling	-	P	-	-	Shire	-	FALSE'